0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MED1

MED1

Brief Information

Name:Sodium channel protein type VIII alpha subunit
Target Synonym:Sodium channel protein type 8 subunit alpha,Sodium channel protein type VIII subunit alpha,MED,SCN8A,Sodium Voltage-Gated Channel Alpha Subunit 8,Voltage-Gated Sodium Channel Subunit Alpha Nav1.6,Sodium Channel, Voltage Gated, Type VIII, Alpha Polypeptide
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Synonym Name

MED1

Background

MED1 (Mediator Subunit1) was identified as a key transcriptional coactivator for ERα during both normal mammary gland development and breast tumorigenesis. MED1 takes a key role for the crosstalk between HER2 and ERα pathway. MED1 regulates ERα-mediated transcription and leads to resistance of breast cancer cells to anti-estrogen therapies.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pirmenol Hydrochloride CI-845 Approved Pfizer Pharmaceuticals Ltd (China), Sumitomo Dainippon Pimavar, Pimenol Japan Arrhythmias, Cardiac null 1994-01-01 Arrhythmias, Cardiac Details
Pilsicainide Hydrochloride DU-6552; SUN-1165 Approved Daiichi Sankyo Co Ltd Sunrythm Japan Tachycardia Daiichi Sankyo Co Ltd 1991-03-29 Tachycardia Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PRAX-330 Phase 1 Clinical Epilepsy Details
PRAX-562 PRAX-562 Praxis Precision Medicines Details
XEN-901 NBI-921352; XEN-901 Phase 2 Clinical Xenon Pharma Brain Diseases; Epilepsy Details

This web search service is supported by Google Inc.

totop